Edition:
Deutschland

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

80.49USD
28 Oct 2020
Change (% chg)

$-2.22 (-2.68%)
Prev Close
$82.71
Open
$81.22
Day's High
$82.21
Day's Low
$80.24
Volume
2,374,880
Avg. Vol
1,702,755
52-wk High
$101.27
52-wk Low
$62.55

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
1.95 Mean rating from 20 analysts

Overall

Beta: 0.68
Market Cap(Mil.): $145,969.41
Shares Outstanding(Mil.): 1,764.83
Dividend: 1.18
Yield (%): 5.71

REFILE-UPDATE 1-FDA declines to approve Zosano's drug for relieving migraine headaches

Oct 21 The U.S. health regulator has declined to approve Zosano Pharma Corp's experimental treatment to relieve pain after the onset of migraine headaches, citing issues with its delivery during clinical trials, the company said on Wednesday.

Photo

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

NIH tests therapies to help cut hospital stays for COVID-19 patients

Oct 16 The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

NIH starts clinical trial testing antibody treatments in COVID-19 patients

Oct 13 The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.

UPDATE 2-J&J raises profit forecast as trial halt weighs

Oct 13 Johnson & Johnson raised its annual profit forecast for the second time this year in quarterly results on Tuesday, a day after it was the second major drug company to call a temporary halt to trials of its experimental coronavirus vaccine.

FACTBOX-Drugmakers rush to develop COVID-19 treatments

(Updates AstraZeneca, Gilead and Vir) Oct 12 Drugmakers around the world are rushing to develop treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Several companies are developing antibody treatments, similar to Regeneron Pharmaceutical Inc's treatment given to U.S. President Donald Trump for his COVID-19 infection. The following is a list of major companies that are developing treatments. For a separate F

HIV treatment has no benefit for hospitalised COVID-19 patients - study

LONDON A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initial results of a large-scale randomised trial of the drug.

HIV treatment has no benefit for hospitalised COVID-19 patients - study

LONDON, Oct 5 A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initial results of a large-scale randomised trial of the drug.

Photo

U.S. court voids $448 million award against AbbVie, but revives FTC claim over AndroGel

A federal appeals court on Wednesday threw out an order requiring AbbVie Inc and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.07%
Rohstoffe +0.02%
Industrie +0.01%
Konjunktur abhängige Waren & Dienstleistungen +0.08%
Konjunktur unabhängige Waren & Dienstleistungen +0.05%
Finanzindustrie +0.01%
Pharma +0.04%
Technologie +0.00%